Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The development of new strategies for the induction of potent and broad immune responses is of high priority in the vaccine field. In this setting, integrase-defective lentiviral vectors (IDLV) represent a new and promising delivery system for immunization purposes. AREAS COVERED: In this review we describe the development and application of IDLV for vaccination. IDLV are turning out to be a new class of vectors endowed with peculiar characteristics, setting them apart from the parental integration-competent lentiviral vectors. Recent data suggest that IDLV are able to induce strong antigen-specific immune responses in terms of quantity, persistence and quality of CD8(+) T cell response following a single immunization in mice. EXPERT OPINION: IDLV are a recent acquisition in the field of genetic immunization, thus allowing for the opportunity of further upgrading, including increasing antigen expression and potency of immune response. Based on recent reports showing the potential of IDLV for immunization in mouse models, further development and validation of IDLV, including comparison with other vaccine protocols and use in non-human primate models, are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“By preventing viral integration, these compounds, such as RAL and EVG, have been shown to inhibit subsequent viral production while maintaining and favouring production of E-DNA with respect to the integrated counterpart [84-88], thus recapitulating the effects obtained in vitro after infection with IDLV and IN-defect…”
ResultAdenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 2×
“Importantly, recent reports have shown that in vivo-delivered IDLV persist in a model animal for up to one year from the inoculum in non dividing cells or tissues [43-48].”
BackgroundMethodPhilippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249 · cited 1×
“Importantly, recent reports have shown that in vivo-delivered IDLV persist in a model animal for up to one year from the inoculum in non dividing cells or tissues [43-48].”
BackgroundIntegration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174 · cited 1×
“Importantly, recent reports have shown that in vivo-delivered IDLV persist in a model animal for up to one year from the inoculum in non dividing cells or tissues [43-48].”
BackgroundRahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
A Large U3 Deletion Causes Increased In Vivo Expression from a Nonintegrating Lentiviral Vector
Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., & Kafri, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.199 · Cited by 94
Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector
Negri, D. R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M. E., & Cara, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300241 · Cited by 84 · cited 4×
“Several reports over the past few years have shown that a single immunizationwith a systemically delivered relatively low dose of IDLVwas sufficient for providing broad and sustained immunization against antigens of viral and tumor origin [50-55], which was higher than that obtained with two injection of naked plasmid…”
BackgroundMethodInfluentialSelf-citationProtective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine
Coutant, F., Frenkiel, M.-P., Despres, P., & Charneau, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003973 · Cited by 70 · cited 5×
“the single immunization was able to protect mice against challenge with wild-type virus and tumor cell lines expressing the model antigen [50,51,53,55].”
BackgroundMethodInfluential
Cited by
(2013) · PubMed · Cited by 308
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Deng, Y., Guan, J., Wen, B., Zhu, N., Chen, H., Song, J., Yang, Y., Wang, Y., & Tan, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062684 · Cited by 21
Gallinaro, A., Borghi, M., Pirillo, M. F., Cecchetti, S., Bona, R., Canitano, A., Michelini, Z., Di Virgilio, A., Olvera, A., Brander, C., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.013 · Cited by 15
Self-citationTriple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
del Moral-Sánchez, I., Wee, E. G., Xian, Y., Lee, W.-H., Allen, J. D., Torrents de la Peña, A., Fróes Rocha, R., Ferguson, J., León, A. N., Koekkoek, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00862-8 · Cited by 14
Metadata
- Authors
- Negri, D. R., Michelini, Z., Bona, R., Blasi, M., Filati, P., Leone, P., Rossi, A., Franco, M., & Cara, A.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2011-05-06
- Volume
- 11
- Issue
- 6
- Pages
- 739-750
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2131369436
- Cited by
- 31
- References
- 10
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. https://app.cochat.ai/papers/10.1517/14712598.2011.571670
- The paper
- Negri, D. R., Michelini, Z., Bona, R., Blasi, M., Filati, P., Leone, P., Rossi, A., Franco, M., & Cara, A. (2011). Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2011.571670
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.